Connect your AI

Aclaris Therapeutics ACRS AFS Securities

AFS Securities at other companies

Shattuck Labs, Inc.STTK

$88.86M+48.6%

Kymera TherapeuticsKYMR

$894.72M+186%

Arcus BiosciencesRCUS

$54M+575%

IncyteINCY

——

Other financials

Income statement

Revenue$2.0M+37.2%

Gross profit$1.6M+68.7%

Operating income-$22.2M-22.7%

Net income-$19.8M-31.4%

EPS (diluted)-$0.15-25.0%

Balance sheet

Cash & equivalents$28.7M-5.6%

Total debt$2.0M-20.1%

Total equity$143.6M-0.3%

Total assets$198.7M+0.3%

Cash flow

Operating cash flow-$18.1M-39.0%

CapEx$13.0K-69.8%

Free cash flow-$18.2M-38.6%

Valuation

Market cap$685.75M+337%

Enterprise value$659.07M+410%

P/S82×+73.1×

Profitability

Gross margin76.3%-9.7pp

Operating margin-961.9%+259pp

Net margin-832.6%+132pp

FCF margin-624.9%—

Returns & leverage

Return on equity-48.4%-15.4pp

Debt / equity0×0.0×

Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Aclaris Therapeutics's AFS securities?: Aclaris Therapeutics (ACRS) reported AFS securities of $85.37M in Q1 2026.
How has Aclaris Therapeutics's AFS securities changed year-over-year?: Aclaris Therapeutics's AFS securities increased by 0.2% year-over-year, from $85.21M to $85.37M.
What is the long-term trend for Aclaris Therapeutics's AFS securities?: Over 4 years (2021 to 2025), Aclaris Therapeutics's AFS securities has grown at a 15.3% compound annual growth rate (CAGR), from $34.24M to $60.61M.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.